ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 1023 • ACR Convergence 2022

    Are We Treating-to-target in Spondyloarthritis (SpA)? A Cross Sectional Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry

    Isaac Cheng1, Ying Ying Leung2, Ho SO1, Praveena Chiowchanwisawakit3, Stanley Angkodjojo4, Muhammad Saeed5, Kichul Shin6, Han Joo Baek7, Mohit Goyal8, Muhammad Haroon9, Eman Satti10, Nallasivan Subramanian11, Fariz Yahya12, Soosan Soroosh13, ASAL ADNAN RIDHA14, Ho Yin Chung15, James Cheng-Chung WEI16, Kishimoto Mitsumasa17 and Lai-shan Tam1, 1The Chinese University of Hong Kong, Hong Kong, China, 2Rheumatology Department, Singapore General Hospital, Singapore, Singapore, 3Mahidol University, Bangkok, Thailand, 4Sengkang General Hospital / Singhealth, Singapore, Singapore, 5Central Park Medical College, Lahore, Pakistan, 6Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, 7Gachon University College of Medicine, Inchon, Republic of Korea, 8CARE Pain & Arthritis Centre, Udaipur, India, 9Doctor, Tralee, Ireland, 10Hamad Medical Corporation, Doha, Qatar, 11Velammal Medical College Hospital, Velammal, India, 12University of Malaya, Kuala Lumpur, Malaysia, 13Army University for Medical School, Tehran, Iran, 14Baghdad Teaching Hospital, Baghdad, Iraq, 15Chiron Medical, Hong Kong, Hong Kong, 16Chung Shan Medical University Hospital, Taichung, Taiwan, 17Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan

    Background/Purpose: Data on the extent to which internationally agreed treat-to-target (T2T) recommendations were applied in clinical practice in patients with SpA across the Asia-Pacific region…
  • Abstract Number: 2217 • ACR Convergence 2022

    Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity

    Amir Razmjou1, Jennifer Wang1, Ani Shahbazian1, Jeffrey Curtis2, Dimitrios Pappas3, Joel Kremer4 and Christina Charles-Schoeman5, 1UCLA Medical Center, Los Angeles, CA, 2University of Alabama at Birmingham, Hoover, AL, 3CorEvitas, LLC, Waltham, MA, 4The Corrona Research Foundation, Delray Beach, FL, 5Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA

    Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme with paraoxonase, lactonase, and arylesterase activities (1). PON1 is integral to the anti-inflammatory, anti-atherogenic functions of…
  • Abstract Number: 1053 • ACR Convergence 2022

    The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Resource Utilization and Gastrointestinal Tract Symptoms in Early Disease

    Sarah Luebker1, Tracy Frech1, Shervin Assassi2, Jessica Gordon3, Elana Bernstein4, Virginia Steen5, Laura Hummers6, Ami Shah7, Carrie Richardson8, Dinesh Khanna9, Flavia Castelino10, Lorinda Chung11, Faye Hant12, Vicki Shanmugam13, John VanBuren14, Jessica Alvey14, Monica Harding14, Luke Evnin15 and Nora Sandorfi16, 1Vanderbilt University Medical Center, Nashville, TN, 2McGovern Medical School, University of Texas, Houston, TX, 3Hospital for Special Surgery, New York, NY, 4Columbia University, New York, NY, 5Georgetown University School of Medicine, Washington, DC, 6Johns Hopkins Univerisity, Baltimore, MD, 7Johns Hopkins Rheumatology, Baltimore, MD, 8Northwestern University, Chicago, IL, 9Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 10Massachusetts General Hospital, Boston, MA, 11Stanford University, Stanford, CA, 12Medical University of South Carolina, Charleston, SC, 13George Washington University, Washington, DC, 14University of Utah, Salt Lake City, UT, 15Scleroderma Research Foundation, Brisbane, CA, 16University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Health costs and resource utilization are important in chronic disease management. Systemic sclerosis (SSc) is a multi-organ system disease with outcomes that are often…
  • Abstract Number: 2268 • ACR Convergence 2022

    Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Cecile Yelnik1, Zeynep Belce Erton2, Elodie Drumez3, Dachi Cheildze2, Danieli Castro Oliveira de Andrade4, Ann E Clarke5, Maria G. Tektonidou6, Vittorio Pengo7, Savino Sciascia8, Amaia Ugarte9, H Michael Belmont10, Mª Angeles Aguirre11, Paul fortin12, maria gerosa13, Flavio Victor Signorelli14, Tatsuya Atsumi15, Zhouli Zhang16, Hannah Cohen17, D. Ware Branch18, Denis Wahl19, Laura Andreoli20, Esther Rodriguez Almaraz21, Michelle Petri22, Ricard Cervera23, Yu Zuo24, Bahar Artim-Esen25, Guillermo Pons-Estel26, Rohan Willis27, Maria Laura Bertolaccini28, Robert Roubey29, Doruk Erkan2 and on behalf of APS ACTION On Behalf Of APS ACTION2, 1Lille University, Lille, France, 2Hospital for Special Surgery, New York, NY, 3Université de Lille, Lille, France, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 6National and Kapodistrian University of Athens, Athens, Greece, 7Padova University Hospital, Padova, Italy, 8University of Turin, Torino, Italy, 9BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, 10NYU School of Medicine, New York, NY, 11Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, 12CHU de Québec, Pavillon CHUL, Québec, Canada, 13University of Milan, Milano, Italy, 14Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 15Hokkaido University, Sapporo, Japan, 16Peking University First Hospital, Beijing, China, 17University College London, London, United Kingdom, 18University of Utah, Salt Lake City, UT, 19Université de Nancy, Nancy, France, 20Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 21Hospital Universitario 12 de Octubre, Madrid, Spain, 22Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 23Hospital Clínic de Barcelona, Barcelona, Spain, 24University of Michigan, Ann Arbor, MI, 25Istanbul University, Istanbul, Turkey, 26CREAR, Rosario, Argentina, 27University of Texas Medical Branch, Galveston, TX, 28King's College London, London, United Kingdom, 29University of North Carolina, Chapel Hill, NC

    Background/Purpose: Long-term anticoagulation is the standard of care for antiphospholipid syndrome (APS) patients with macrovascular thrombosis. However, in daily practice, long-term anticoagulation may not be…
  • Abstract Number: 1084 • ACR Convergence 2022

    Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study

    Xavier Puéchal1, Michele Iudici2, Elodie Perrodeau3, bernard bonnotte4, Francois Lifermann5, Thomas Le Gallou6, Alexandre Karras7, Claire Blanchard-Delaunay8, Thomas Quéméneur9, Achille Aouba10, Olivier Aumaître11, Vincent Cottin12, Mohamed Hamidou13, Marc Ruivard11, Pascal Cohen1, Luc Mouthon1, Loïc Guillevin1, Philippe Ravaud3, Raphaël Porcher3 and Benjamin Terrier1, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 2Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 3Université Paris Cité, Hôtel-Dieu, Paris, France, 4Centre Hospitalo-Universitaire de Dijon, Dijon, France, 5Dax Hospital, Dax, France, 6Rennes Sud University Hospital, Rennes, France, 7HEGP, Paris, France, 8Niort Hospital, Niort, France, 9Valenciennes Hospital, Valenciennes, France, 10Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, 11Clermont Ferrand University Hospital, Clermont-Ferrand, France, 12Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 13Nantes University Hospital, Nantes, France

    Background/Purpose: Randomized controlled trials showed rituximab (RTX)'s non-inferiority to cyclophosphamide (CYC) for induction therapy of ANCA-associated vasculitis and neither treatment was favoured in granulomatosis with…
  • Abstract Number: 0072 • ACR Convergence 2022

    Geographical Patterns of Healthcare Utilization Among RA and OA Patients

    Sofia Pedro1, Luke Desilet2, Patricia Katz3 and Kaleb Michaud2, 1Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 2University of Nebraska Medical Center, Omaha, NE, 3UCSF, San Rafael, CA

    Background/Purpose: Rural residence has been associated with disparities in healthcare-related outcomes in both rheumatic diseases and other chronic conditions. A primary causal pathway for this…
  • Abstract Number: 1218 • ACR Convergence 2022

    Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry

    Philip J Mease1, Alexis Ogdie2, Dimitrios Pappas3, George Reed4 and Joel Kremer5, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3CorEvitas, LLC, Waltham, MA, 4The Corrona Research Foundation and University of Massachusetts, Albany, NY, 5The Corrona Research Foundation, Delray Beach, FL

    Background/Purpose: Fibromyalgia (FM) occurs concomitantly with inflammatory rheumatic disease, including psoriatic arthritis (PsA), in up to 20% of patients and chronic widespread pain (CWP) in…
  • Abstract Number: 0258 • ACR Convergence 2022

    Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents

    Sascha Heckert1, Tjardo Maarseveen2, Emiel Marges2, Arvind Chopra3, David Vega Morales4, Riette Du Toit5, Annette van der Helm-van Mil6, Tom Huizinga2, CF Allaart2 and Sytske Anne Bergstra7, 1Leiden University Medical Centre, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Center for Rheumatic Diseases, Pune, Maharashtra, India, 4Hospital General de Zona 17, Instituto Mexicano del Seguro Social, Monterrey, Mexico, 5Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa, 6Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, 7LUMC, Leiden, Netherlands

    Background/Purpose: Interstitial lung disease (ILD) is a spectrum of inflammatory and fibrotic lung diseases, and can be associated with RA (RA-ILD). The reported prevalence in…
  • Abstract Number: 1308 • ACR Convergence 2022

    Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study

    Diala Alawneh1, Moustafa Younis2, Romesa Hassan1, Bashar Alzghoul2, Shiva Arami1, Tricha Shivas3, Mary McGowan3, Khaldoon Alawneh4, Christian Ascoli1 and Nadera Sweiss1, 1University of Illinois at Chicago, Chicago, IL, 2University of Florida, Gainesville, FL, 3Foundation for Sarcoidosis Research, Chicago, IL, 4Jordan University of Science and Technology, Irbid, Jordan

    Background/Purpose: Patients with sarcoidosis are at an increased risk of developing osteoporosis due to the active inflammatory state and chronic corticosteroid use. Proper dosing of…
  • Abstract Number: 0289 • ACR Convergence 2022

    Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry

    Song-Chou Hsieh1, Wei-Sheng Chen2, Jui-Chieh Hu3, Wan-Yu Sung4, Wen-Chan Tsai4, Hsiang-Cheng Chen5, Chung-Ming Huang6, Edward Kuo7, James Wee8, John Woolcott9 and Yi-Hsing Chen10, 1Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 2Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, 3Division of Allergy, Immunology and Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 4Department of Allergy, Immunology, and Rheumatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 5Division of Immunology, Rheumatology, and Allergy, Department of Medicine, Tri-Service General Hospital, Taipei, Taiwan, 6Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, 7Pfizer Ltd, Taipei, Taiwan, 8Pfizer Inc, Makati City, Philippines, 9Pfizer, Inc, Collegeville, PA, 10Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and was approved under Taiwan's National Health Insurance (NHI) reimbursement system in…
  • Abstract Number: 1318 • ACR Convergence 2022

    Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure

    Edgar Wiebe1, Dörte Huscher2, Desirée Schaumburg1, Andriko Palmowski1, Sandra Hermann1, Thomas Buttgereit3, Robert Biesen4, Gerd Burmester5, Yannick Palmowski6, Maarten Boers7, John Stone8, Christian Dejaco9 and Frank Buttgereit10, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 3Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 4Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 5Charité University Medicine Berlin, Berlin, Germany, 6Spine Department, Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 7Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 8Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 9Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 10Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany

    Background/Purpose: Inflammatory rheumatic and musculoskeletal diseases (iRMD) are associated with increased systemic bone loss that is mediated by chronic inflammation, treatment with glucocorticoids (GC), and…
  • Abstract Number: 0290 • ACR Convergence 2022

    Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)

    Kim Lauper1, Romain Aymon2, Denis Mongin2, Sytske Anne Bergstra3, Denis Choquette4, Catalin Codreanu5, Ori Elkayam6, Kimme Hyrich7, Florenzo Iannone8, Nevsun Inanc9, Lianne Kearsley-Fleet10, Tore K. kvien11, Eirik Kristianslund12, Burkhard Leeb13, Galina Lukina14, Dan Nordstrom15, Karel Pavelka16, Manuel Pombo-Suarez17, Ziga Rotar18, Maria José Santos19, Delphine Courvoisier20 and Axel Finckh21, 1Geneva University Hospitals, Genéve, Switzerland, 2Geneva University Hospitals, Geneva, Switzerland, 3LUMC, Leiden, Netherlands, 4Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 5Center for Rheumatic Diseases, Bucharest, Romania, 6Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 7The University of Manchester, Manchester, United Kingdom, 8School of Medicine University of Bari, Bari, Italy, 9Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, 10Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, 11Diakonhjemmet Hospital, Oslo, Norway, 12Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway, 13Bioreg, Stockerau, Austria, 14Federal state budgetary scientific institution �Research Institute of rheumatology named after V. A. Nasonova�, Moscow, Russia, 15Helsinki University Hospital, Helsinki, Finland, 16Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, 17Hospital Clinico Universitario, Santiago de Compostela, Spain, 18University Medical Centre Ljubljana, Ljubljana, Slovenia, 19Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, 20University Hospitals of Geneva, Geneva, Switzerland, 21Geneva University Hospital, Geneve - Vesenaz, Switzerland

    Background/Purpose: The "ORAL Surveillance" study1 suggests an increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to TNF-inhibitors (TNFi). Currently, there…
  • Abstract Number: 1380 • ACR Convergence 2022

    Development of Core and Expanded Datasets to Align Registries and Advance International Collaborative Research for Childhood-onset Systemic Lupus Erythematosus

    Rebecca Sadun1, Laura Lewandowski2, Alexandre Belot3, Eve Smith4 and Jennifer Cooper5, 1Duke University, Durham, NC, 2NIAMS, NIH, Bethesda, MD, 3Hospices Civils de Lyon, Collonges au mont d'or, France, 4University of Liverpool, Liverpool, United Kingdom, 5University of Colorado/Children's Hospital Colorado, Denver, CO

    Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) occurs in approximately 20% of all SLE cases. cSLE is has a worse prognosis than adult-onset SLE, often requiring…
  • Abstract Number: 0306 • ACR Convergence 2022

    Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry

    Gabriela Schmajuk1, Nevin Hammam2, Jing Li3, David Collier4, Greg Kricorian5 and Scott Stryker6, 1UCSF / SFVA, San Francisco, CA, 2Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, 3University of California, San Francisco, San Francisco, CA, 4Amgen Inc., Simi Valley, CA, 5Amgen, Inc., Thousand Oaks, CA, 6Amgen Inc., San Francisco, CA

    Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…
  • Abstract Number: 1423 • ACR Convergence 2022

    Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting

    Regan Arendse1, Proton Rahman2, Philip Baer3, Derek Haaland4, Dalton Sholter5, Odalis Asin-Milan6, Meagan Rachich7, Emmanouil Rampakakis8, A. Marilise Marrache9 and Allen J. Lehman10, 1Community Rheumatology Care, Saskatoon, Canada, 2Memorial University, St. John's, NL, Canada, 3Baer Weinberg MPC, Scarborough, ON, Canada, 4The Waterside Clinic, Oro Medonte, ON, Canada, 5University of Alberta, Edmonton, AB, Canada, 6Janssen Canada, Laval, QC, Canada, 7Janssen Inc., Guelph, ON, Canada, 8McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 9Janssen Inc., Dollard-des-Ormeaux, QC, Canada, 10Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Golimumab (GLM), a tumor necrosis factor inhibitor (TNFi), has demonstrated efficacy and a favorable safety profile in inflammatory rheumatic diseases. Recent safety studies with…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology